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Abstract
Background: The effectiveness of hepatoprotective drugs for DIH (drug induced hepatotoxicity) during tuberculosis
treatment is not clear. We evaluated the effectiveness of hepatoprotective drugs by comparing the period until the
normalization of hepatic enzymes between patients who were prescribed with the hepatoprotective drugs after
DIH was occurred and patients who were not prescribed with the hepatoprotective drugs.
Methods: During 2006–2010, 389 patients with active tuberculosis were included in this study. DIH was defined as
elevation of peak serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) of more than twice
the upper limit of normal (ULN). We divided the patients into the severe (peak serum AST and/or ALT elevation of >5
times the ULN), moderate (peak serum AST and/or ALT elevation of >3 to ≤5 times the ULN), and mild DIH groups
(peak serum AST and/or ALT elevation of >2 to ≤3 times the ULN). We compared the average period until the
normalization of hepatic enzymes between patient subgroups with and without hepatoprotective drugs
(ursodeoxycholic acid: UDCA, stronger neo-minophagen C: SNMC, and glycyrrhizin).
Results: In the severe group, there was no significant difference in the average period until the normalization between
subgroups with and without hepatoprotective drugs (21.4 ± 10.8 vs 21.5 ± 11.1 days, P = 0.97). In the mild group, the
period was longer in the subgroup with hepatoprotective drugs than that without hepatoprotective drugs (15.7 ± 6.2
vs 12.4 ± 7.9 days, P = 0.046).
Conclusion: Regardless of the severity, hepatoprotective drugs did not shorten the period until the normalization of
hepatic enzymes.
Background
Tuberculosis (TB) is one of the serious infectious dis-
eases. Isoniazid, rifampicin, and pyrazinamide are the
first-line standard-regimen drugs administered for TB,
but these anti-TB drugs often bring some major adverse
effects such as hepatotoxicity, gastrointestinal and
neurological disorders, and skin reactions [1–3]. Espe-
cially, drug-induced hepatotoxicity (DIH) is one of the
most serious adverse effects ascribed to anti-TB drugs.
Larrey reported that hepatotoxicity accounted for more
than 7.0 % of all adverse effects [4]. Hepatotoxicity
diminishes the effectiveness of anti-TB drugs because it
leads to significantly poor adherence, and eventually it
can lead to not only treatment failure but also recur-
rence of TB and drug-resistance [5, 6].
In 2006, the American Thoracic Society (ATS) re-
ported that the frequency of DIH ranged from 5 to 33 %,
and the risk factors included age over 35, female sex,
alcohol use, preexisting liver damage, the presence of
rifampicin in a multidrug treatment regimen, history of
viral hepatitis, and use of second-line anti-TB agents [7].
Thereafter, many studies have also shown the relation-
ship between DIH and risk factors, but few have shown
the relationship between DIH and hepatoprotective
drugs. Although there is no consensus on their effective-
ness against DIH, hepatoprotective drugs have often
been used empirically in patients with DIH, such as
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herbal medicine. If hepatoprotective drugs improve
hepatic enzymes in patients suffering from DIH, it may
be possible to prevent interruption and failure of treat-
ment. Therefore, we evaluated the effectiveness of hepa-
toprotective drugs by comparing the period until the
normalization of hepatic enzymes between patients with
and without hepatoprotective drugs.
The purpose of this study was to investigate the effect-
iveness of several hepatoprotective drugs (ursodeoxycholic
acid: UDCA, stronger neo-minophagen C: SNMC, and
glycyrrhizin) in patients with hepatic enzyme elevation
owing to anti-TB drugs.
Hepatoprotective drugs
UDCA, SNMC, and glycyrrhizin are often used in Japan
as hepatoprotective drugs.
UDCA
UDCA, a hydrophilic dihydroxylated bile acid, was first
identified as a major constituent of the dried bile of the
Chinese black bear. Reports on a beneficial effect on
serum liver tests in cholestatic disorders were first pub-
lished in Western literature [8–10]. The structure of
UDCA was already elucidated in 1936 by Iwasaki [11],
and the effectiveness of UDCA against chronic hepatitis
was first reported in 1961 [12, 13]. Since then, many
studies have shown the effectiveness of UDCA in
chronic hepatitis, and the mechanism of its action has
been recognized as (1) replacement/displacement of
toxic endogenous bile acids, (2) cytoprotective effects on
hepatocytes and bile duct epithelial cells, (3) immuno-
modulatory effects, and (4) stimulation of bile secretion
by hepatocytes and bile duct epithelial cells [14–16].
SNMC
SNMC, an intravenous drug, contains glycyrrhizin as a
principal ingredient as well as glycine and L-cysteine. It
has been used to treat chronic hepatitis for over 30 years
in Japan and has been shown to be effective in prevent-
ing hepatocellular carcinoma development in patients
with chronic hepatitis C; however, its underlying mecha-
nisms of action remain to be elucidated [17]. In Japan,
SNMC has been used for treating allergic diseases since
1948 and was also used for treating chronic liver disease.
Suzuki et al. reported that serum levels of AST, ALT,
and γ-GTP can be significantly reduced by SNMC [18].
In Japan, the use of SNMC has been approved for man-
aging liver function abnormalities in chronic liver dis-
ease since 1979.
Glycyrrhizin
Glycyrrhizin, a conjugate of one molecule of glycyrrheti-
nic acid with two molecules of glucuronic acid, is ex-
tracted from the roots of the Glycyrrhiza glabra plant
has been used for treating chronic hepatitis for over
20 years [19]. It has been used as an anti-allergic agent
in traditional Chinese medicine and as a food additive in
beverages and licorice because of its sweet taste [20]. In
1946, Revers reported on the anti-ulcer effect of licorice
[21]. Since then, glycyrrhizin has been used in Europe as
an anti-ulcer drug for several years. In 1977, Suzuki
et al. reported that the plasma transaminase activity in a
group of patients with chronic active liver disease
treated with glycyrrhizin improved significantly com-
pared to the placebo-treated group [18]. However, the
mechanism of action of glycyrrhizin remains unknown.
Association between hepatotoxicity and the isoniazid
metabolic pathway
An association between hepatotoxicity and the isoniazid
metabolic pathway has been reported in recent studies
[22–27]. According to these studies, the predominant
metabolic pathway of isoniazid metabolism is acetylation
by the hepatic enzyme N-acetyltransferase 2. As the
acetylation rate in humans is genetically determined,
humans can be categorized into slow and rapid acetyla-
tors. In rapid acetylators, isoniazid is acetylated into
acetylisoniazid and then excreted as diacetylhydrazine
via acetylhydrazine. In slow acetylators, however, isoniazid
is directly hydrolyzed into isonicotinic acid and hydrazine.
These studies have concluded that this hydrazine is the
most likely cause of isoniazid-induced hepatotoxicity. The
mechanism of rifampicin- and pyrazinamide-induced hep-
atotoxicity remains unclear, but it is known that rifampicin
increases isoniazid hydrolase activity and production of the
hepatotoxic metabolite of isoniazid in slow acetylators [28].
Methods
Study population and treatment
The study population included all patients with active
TB diagnosed by smear, culture, or polymerase chain re-
action (PCR) analysis of sputum specimens, gastric
washing, or bronchoalveolar lavage between January
2006 and December 2010 at the Jikei University Daisan
Hospital. Clinical data were obtained retrospectively
from medical records. Blood tests were preformed at
least once a week during the initial 2 months of TB ther-
apy. All patients received first-line standard-regimen
drugs such as daily isoniazid, rifampicin, and ethambutol
(HRE regimen) or isoniazid, rifampicin, ethambutol, and
pyrazinamide (HREZ regimen). According to the Japanese
Society for TB, the dosages of anti-TB drugs were 5 mg/
kg/day (maximum 300 mg/day) of isoniazid, 10 mg/kg/
day (maximum 600 mg/day) of rifampicin, 25 mg/kg/day
(maximum 750 mg/day) of ethambutol, and 25 mg/kg/day
(maximum 1.5 g/day) of pyrazinamide [29]. This study
was approved by the institutional ethical committee at
The Jikei University School of Medicine.
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Definition of anti-TB DIH
According to the Japanese Society of TB, anti-TB DIH
was evaluated by serum aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and total biliru-
bin values. All patients in the present study have an
increase of serum AST and ALT, but few patients have
an increase of total bilirubin. As a result, we evaluated
the serum AST and ALT as markers of hepatotoxicity.
The normal range of serum AST and ALT was defined
as less than 30 U/L by referring the Japanese Society of
Laboratory Medicine. Also, DIH was defined as elevation
of peak serum and/or ALT > 2 times the upper limit of
normal (ULN) from the beginning of treatment. All
patients with DIH were divided into three groups as
shown in Fig. 1. First, the patients with DIH were divided
into the severe, mild, and moderate DIH groups by the
severity of their hepatotoxicity. The severe DIH group was
defined as elevation of peak serum AST and/or ALT > 5
times the ULN. The moderate group was defined as eleva-
tion of peak AST and/or ALT > 3 to ≤ 5 times the ULN.
The mild DIH group was defined as elevation of peak
serum AST and/or ALT > 2 to ≤ 3 times the ULN. Next,
these groups were divided into subgroups of patients with
and without hepatoprotective drugs. The following pa-
tients were excluded: (1) patients with a history of liver
disease such as viral hepatitis or other liver diseases, and
(2) patients with a serum AST and/or ALT > the ULN
before anti-TB treatment.
Management of hepatotoxicity
When DIH occurred, anti-TB drugs were continued in
all patients within the moderate and mild DIH groups,
but these drugs were stopped immediately in all patients
within the severe DIH group. Then, the decision of
whether to use hepatoprotective drugs in all of the pa-
tients with hepatotoxicity was based on the judgment of
the attending physicians.
Comparison factor between patients with and without
hepatoprotective drugs
The purpose was to investigate retrospectively the effect-
iveness of hepatoprotective drugs in patients with hepatic
enzyme elevation owing to anti-TB drugs. We retrospect-
ively obtained the clinical data from medical records, and
compared the average period until the normalization of
the hepatic enzymes between patients with and without
hepatoprotective drugs. We evaluated statistically the ef-
fectiveness of hepatoprotective drugs by comparing the
differences of this period.
Statistical analysis
The Mann-Whitney U test was used to compare the dif-
ferences in average values, and the chi-square test was
used to compare paired proportions. A P value < 0.05
indicated statistical significance for all analyses. All stat-
istical analyses were performed with SPSS software,
version 20.0 (SPSS Inc., Chicago, IL, USA).
Results and discussion
Baseline characteristics of the patients with DIH
Of the 389 patients diagnosed as having active TB, 71
(18 %) were identified as developing DIH, of whom 23
patients were assigned to the severe, 5 patients to the
moderate, and 43 patients to the mild DIH groups.
However, it was impossible to include the moderate
group in the analysis because the number of applicable
patients was too low. In the severe DIH group, 17
Fig. 1 Patient selection flow chart. Of the 389 patients diagnosed as active TB, 71 was identified to develop DIH, with 23 patients assigned to the
severe, five patients to the moderate, and 43 patients to the mild DIH group
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patients received hepatoprotective drugs and 6 patients
did not. In the mild DIH group, 10 patients received
hepatoprotective drugs and 33 patients did not. There
were no significant differences in sex and age between
the subgroups with and without hepatoprotective drugs
as shown in Tables 1 and 2. Peak AST/ALT levels tended
to be higher in each group with hepatoprotective drugs,
but the differences were not significant.
Average period until the normalization of hepatic
enzymes
In the severe DIH group, as shown in Table 3, there
was no significant difference in the average period until
the normalization of the hepatic enzymes between the
patient subgroups with and without hepatoprotective
drugs (21.4 ± 10.8 vs 21.5 ± 11.1 days, P = 0.97). As
shown in Table 4, the average period until the
normalization in the mild group was longer in the
subgroup with hepatoprotective drugs than in the sub-
group without (15.7 ± 6.2 vs 12.4 ± 7.9 days, P = 0.046).
Average period until the normalization of hepatic
enzymes in the HREZ regimen group
All patients received first-line standard-regimen drugs
such as HRE or HREZ regimen. The patients of HREZ
regimen and not HRE regimen have a higher risk of hep-
atotoxicity than the patients of HRE regimen and not
HREZ regimen because pyrazinamide have hepatotox-
icity as side effect. Among the patients treated with the
HREZ regimen in the severe DIH group, as shown in
Table 3, there was no significant difference in the aver-
age period until the normalization of hepatic enzymes
between those with and without hepatoprotective drugs
(21 ± 8 vs 24 ± 10 days, P = 0.64). Of the patients treated
with the HREZ regimen in the mild DIH group, as
shown in Table 4, there also was no significant difference
in the average period until the normalization of hepatic
enzymes between those with and without hepatoprotec-
tive drugs (16 ± 7 vs 13 ± 9 days, P = 0.061).
Flow of the design and definition decisions
The present study showed that hepatoprotective drugs did
not shorten the period until the normalization of hepatic
enzymes regardless of the severity of the hepatotoxicity
caused by anti-TB drugs. Miyazawa et al. reported in 2003
that glycyrrhizin, one of the hepatoprotective drugs, was
not effective in patients with elevated hepatic enzymes
owing to anti-TB drugs [30]. To our knowledge, however,
no study reported subsequently on the relationship be-
tween anti-TB DIH and hepatoprotective drugs. From this
point of view, the present study has great value in terms
of investigating the effectiveness of hepatoprotective drugs
including UDCA and SNMC. Also, these hepaprotective
drugs have never been evaluated the possibility of prophy-
lactic effect. We believe that it is worth discussing this
possibility as another potential prospective study.
Many risk factors are associated with DIH. In particu-
lar, several studies have reported a positive association
between viral hepatitis and DIH [31–33]. In the present
study, we excluded those patients with viral hepatitis
and other liver disease to eliminate the possibility of
Table 1 Baseline characteristics of the 23 patients with severe
drug-induced hepatotoxicity
Patients who stopped












Age, years 64 ± 20 58 ± 22 0.58
Peak AST
(IU/dl)
477 ± 404 278 ± 156 0.31
Peak ALT
(IU/dl)
362 ± 188 262 ± 132 0.55
Data are expressed as number or means ± standard error
TB tuberculosis, AST aspartate aminotransferase, ALT alanine aminotransferase




drugs (N = 10)
Patients without
hepatoprotective





Age (years) 57 ± 21 55 ± 23 0.80
Peak AST
(IU/dl)
66 ± 19 58 ± 12 0.20
Peak ALT
(IU/dl)
72 ± 21 54 ± 21 0.058
Data are expressed as number or means ± standard error
AST aspartate aminotransferase, ALT alanine aminotransferase
Table 3 Comparison of the average period until normalization













severe DIH group 21 ± 10 days
(N = 17)
21 ± 11 days
(N = 6)
0.97
HREZ group 21 ± 8 days
(N = 11)
24 ± 10 days
(N = 5)
0.64
Data are expressed as means ± standard error
Abbreviations: H isoniazid, R rifampicin, E ethambutol, Z pyrazinamide
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DIH other than that of liver enzyme elevation occurring
during TB treatment.
As per the hepatotoxicity definition, both the ATS
and the British Thoracic Society (BTS) have recom-
mended that potentially hepatotoxic medications
should be halted if the serum ALT exceeds 5 times
the ULN (with or without symptoms) or 3 times the
ULN with jaundice and/or hepatitis symptoms. Fur-
thermore, regular monitoring of liver function is rec-
ommended when the serum ALT is > 2 times the
ULN. Otherwise, the Japanese Society for TB recom-
mends that medications should be stopped if serum
AST and/or ALT exceed either 5 times the ULN (with
or without symptoms) or 3 times the ULN with
symptoms. Referring to these recommendations, we
defined DIH as an elevation of peak serum AST and/
or ALT of > 2 times the ULN to detect more patients
with DIH [34]. DIH occurred in 18 % of patients who
underwent anti-TB treatment in the present study.
Although a wide definition of DIH was used in the
present study in comparison with that of the ATS
and the BTS, the percent of patients with DIH was
similar to that in several previous studies [35, 36].
The ATS has also recommended that anti-TB drugs
should be resumed after the serum ALT level drops
to < 2 times the ULN. In present study, we resumed
anti-TB drugs in all patients after both serum AST
and ALT returned to normal levels.
Limitations of the present study
The present study has some limitations. First, because
this is a retrospective study, the medication period and
dosage of hepatoprotective drugs were not unified. Some
patients were treated with two or more hepatoprotective
drugs at the same time. Therefore, we could not evaluate
the effectiveness of each hepatoprotective drugs indi-
vidually. To our knowledge, the action of mechanism for
Glycyrrhizin, SNMC, and UDCA were not clarified com-
pletely. We believe that it is necessary to examine the ef-
ficacy of each drug separately in a future prospective
study. Second, we excluded the moderate DIH group
because it comprised only 5 applicable patients. We also
defined DIH as an elevation of peak serum AST and/or
ALT > 2 times the ULN to detect more patients with
DIH, but only 71 patients fit our criteria. Further investi-
gation via a large prospective study is necessary in the
future. Third, UDCA, SNMC, and glycyrrhizin are nor-
mally used for viral hepatitis and cholelithiasis, but the
use of these hepatoprotective drugs for DIH has never
been permitted as health care services provided by
health insurance in Japan. This fact may delay investiga-
tion into the association between DIH and hepatopro-
tective drugs. Despite the above limitations, we believe
this study has valuable implications for clinical practice.
Conclusion
In patients with active TB, hepatoprotective drugs did
not appear to shorten the period until the normalization
of hepatic enzymes, regardless of the severity of the
hepatotoxicity caused by anti-TB drugs.
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